Table 2.
Baseline characteristics of subjects for long-term analysis set.
| Demographics | Imidafenacin | Solifenacin | P-value | |
|---|---|---|---|---|
| Subjects | 11 | 14 | ||
| Age (years) | (Mean ± SD) | 69.9 ± 6.7 | 71.4 ± 6.0 | 0.5560a |
| <60, n (%) | 0 (0%) | 0 (0%) | ||
| ≥60, n (%) | 4 (36.4%) | 4 (28.6%) | ||
| ≥70, n (%) | 7 (63.6%) | 10 (71.4%) | ||
| Gender | ||||
| Male, n (%) | 7 (63.6%) | 10 (71.4%) | 1.0000b | |
| Female, n (%) | 4 (36.4%) | 4 (28.6%) | ||
| OABSS (total score) | (Mean ± SD) | 9.0 ± 1.3 | 8.9 ± 2.6 | 0.8453c |
| Siverity of OABSS | ||||
| Mild, n (%) | 0 (0%) | 3 (21.4%) | 0.3671c | |
| Moderate, n (%) | 11 (100%) | 10 (71.4%) | ||
| Severe, n (%) | 0 (0%) | 1 (7.1%) | ||
| Postvoid residual volume (mL) | (Mean ± SD) | 15.1 ± 14.7 | 13.4 ± 11.0 | 0.7487a |
| Each urination volume (mL) | (Mean ± SD) | 125.3 ± 85.0 | 203.8 ± 179.8 | 0.1654a |
| Urination time (second) | (Mean ± SD) | 29.1 ± 23.0 | 26.1 ± 10.7 | 0.6939a |
| Qmax (mL/s) | (Mean ± SD) | 11.2 ± 8.8 | 14.8 ± 11.8 | 0.4120a |
| In male | ||||
| Prostate volume (mL) | (Mean ± SD) | 21.0 ± 9.1 | 27.8 ± 8.2 | 0.1302a |
| Use of α1 blocker, n (%) | 6 (85.7%) | 9 (90.0%) | 1.0000b |
Severity of OAB was defined as total OABSS score ≤5: mild; 6 to ≤11: moderate; ≥12: severe
a: Unpaired t-test, b: Fisher's exact test, c: Mann-Whitney U test, two-sided. SD: standard deviation.